{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:32:40Z","timestamp":1790688760767,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T00:00:00Z","timestamp":1424822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI068641"],"award-info":[{"award-number":["U01 AI068641"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2015,4]]},"abstract":"Objectives<\/jats:title>With HIV<\/jats:styled-content> treatment prolonging survival and HIV<\/jats:styled-content> infection now managed as a chronic illness, quality of life (QOL<\/jats:styled-content>) is important to evaluate in persons living with HIV<\/jats:styled-content> (PLWH<\/jats:styled-content>). We assessed at study entry the QOL<\/jats:styled-content> of antiretroviral\u2010na\u00efve PLWH<\/jats:styled-content> with CD4 counts >\u2009500 cells\/\u03bcL in the Strategic Timing of AntiRetroviral Treatment (START<\/jats:styled-content>) clinical trial.<\/jats:p><\/jats:sec>Methods<\/jats:title>QOL<\/jats:styled-content> was assessed with: (1) a visual analogue scale (VAS<\/jats:styled-content>) for self\u2010assessment of overall current health; (2) the Short\u2010Form 12\u2010Item Version 2 Health Survey\u00ae<\/jats:sup> (SF<\/jats:styled-content>\u201012V2), for which responses are summarized into eight individual QOL<\/jats:styled-content> domains plus component summary scores for physical health [the Physical Health Component Summary (PCS<\/jats:styled-content>)] and mental health [the Mental Health Component Summary (MCS<\/jats:styled-content>)]. The VAS<\/jats:styled-content> and eight domain scores were scaled from 0 to 100. Mean QOL<\/jats:styled-content> measures were calculated overall and by demographic, clinical and behavioural factors.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 4631 participants completed the VAS<\/jats:styled-content> and 4119 the SF<\/jats:styled-content>\u201012. The mean VAS<\/jats:styled-content> score (with standard deviation) was 80.9\u2009\u00b1\u200915.7. Mean SF<\/jats:styled-content>\u201012 domain scores were lowest for vitality (66.3\u2009\u00b1\u200926.4) and mental health (68.6\u2009\u00b1\u200921.4), and highest for physical functioning (89.3\u2009\u00b1\u200923.0) and bodily pain (88.0\u2009\u00b1\u200921.4). Using multiple linear regression, PCS<\/jats:styled-content> scores were lower (P<\/jats:italic>\u2009<\u20090.001) for A<\/jats:styled-content>sians, N<\/jats:styled-content>orth A<\/jats:styled-content>mericans, female participants, older participants, and those with less education, longer duration of known HIV<\/jats:styled-content> infection, alcoholism\/substance dependence and body mass index \u2265\u200930\u2009kg\/m2<\/jats:sup>. MCS<\/jats:styled-content> scores were highest (P<\/jats:italic>\u2009<\u20090.001) for A<\/jats:styled-content>fricans, S<\/jats:styled-content>outh A<\/jats:styled-content>mericans and older participants, and lowest for female participants, current smokers and those with alcoholism\/substance dependence.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In this primarily healthy population, QOL<\/jats:styled-content> was mostly favourable, emphasizing that it is important that HIV<\/jats:styled-content> treatments do not negatively impact QOL<\/jats:styled-content>. Self\u2010assessed physical health summary scores were higher than mental health scores. Factors such as older age and geographical region had different effects on perceived physical and mental health.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12237","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T09:55:37Z","timestamp":1424858137000},"page":"88-96","source":"Crossref","is-referenced-by-count":24,"title":["Quality of life assessment among HIV<\/scp>\u2010positive persons entering the INSIGHT<\/scp> Strategic Timing of AntiRetroviral Treatment (START<\/scp>) trial"],"prefix":"10.1111","volume":"16","author":[{"given":"AR","family":"Lifson","sequence":"first","affiliation":[{"name":"University of Minnesota Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GA","family":"Grandits","sequence":"additional","affiliation":[{"name":"University of Minnesota Minneapolis MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EM","family":"Gardner","sequence":"additional","affiliation":[{"name":"Denver Public Health Denver CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MJ","family":"Wolff","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Arriar\u00e1n Santiago Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Pulik","sequence":"additional","affiliation":[{"name":"Hospital for Infectious Diseases Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Williams","sequence":"additional","affiliation":[{"name":"University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WJ","family":"Burman","sequence":"additional","affiliation":[{"name":"Denver Public Health Denver CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(94)90129-5"},{"key":"e_1_2_8_3_1","first-page":"1","volume-title":"Measuring Health Days: Population Assessment of Health\u2010Related Quality of Life","author":"Centers for Disease Control and Prevention","year":"2000"},{"key":"e_1_2_8_4_1","unstructured":"Preamble to the constitution of the World Health Organization as adopted by the International Health Conference New York 19 June \u2013 22 July 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization no. 2 p. 100) and entered into force on 7 April 1948."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-006-9001-7"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-4-19"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-007-9214-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm499"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815acaa4"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/649216"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-8-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/HIV.S32321"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01609.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01020.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12112"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2013.0203"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0040-4"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120500359298"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200208150-00004"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1545109712456429"},{"key":"e_1_2_8_21_1","volume-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for A Public Health Approach, June 2013","author":"World Health Organization","year":"2013"},{"key":"e_1_2_8_22_1","volume-title":"Guidelines for the Use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2014"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774512440342"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:QURE.0000018499.64574.1f"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199603000-00003"},{"key":"e_1_2_8_26_1","volume-title":"User's Manual for the SF\u201012v2 Health Survey","author":"Ware JE","year":"2009"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.pubmed.a024606"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00109-7"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000182518.84407.32"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2014.01.015"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.08.015"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/nur.10041"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00434949"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.1.18509"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.08.008"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12227"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12237","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T04:24:27Z","timestamp":1694492667000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,25]]},"references-count":35,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/hiv.12237"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12237","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,25]]}}}